Were Analysts Bearish Meridian Bioscience, Inc. (NASDAQ:VIVO) This Week?

Meridian Bioscience, Inc. (NASDAQ:VIVO) Logo
Investors sentiment decreased to 1.13 in 2018 Q4. Its down 0.02, from 1.15 in 2018Q3. It turned negative, as 18 investors sold Meridian Bioscience, Inc. shares while 53 reduced holdings. 34 funds opened positions while 46 raised stakes. 38.14 million shares or 2.14% more from 37.34 million shares in 2018Q3 were reported.
Mutual Of America Cap Mngmt Limited Liability Com holds 0% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO) for 1,056 shares. Comerica Natl Bank has 0.01% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO) for 41,483 shares. Mondrian Investment Prtnrs Ltd has 0.08% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO). The Ontario – Canada-based Royal Savings Bank Of Canada has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Cardinal Capital Mgmt accumulated 30,072 shares. Bluemountain Cap Mngmt Ltd Co owns 39,649 shares. First Republic Investment Incorporated accumulated 0% or 18,714 shares. The Switzerland-based Swiss Natl Bank has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Pnc Finance Service Group Inc reported 98,337 shares or 0% of all its holdings. Manufacturers Life Ins The reported 26,175 shares. Ls Advsr Lc stated it has 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Parametric Port Limited Liability Company reported 0.01% stake. Natl Bank Of Mellon Corporation owns 694,380 shares or 0% of their US portfolio. Hotchkis Wiley Mngmt Limited Co stated it has 0.01% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO). 12,245 are held by Eqis Cap Management.

Since November 12, 2018, it had 0 insider purchases, and 1 sale for $681,229 activity.

Meridian Bioscience, Inc. (NASDAQ:VIVO) Ratings Coverage

Among 2 analysts covering Meridian Bioscience (NASDAQ:VIVO), 0 have Buy rating, 1 Sell and 1 Hold. Therefore 0 are positive. Meridian Bioscience had 6 analyst reports since February 19, 2019 according to SRatingsIntel. The company was maintained on Wednesday, May 1 by Canaccord Genuity. The company was upgraded on Wednesday, May 1 by Piper Jaffray. Below is a list of Meridian Bioscience, Inc. (NASDAQ:VIVO) latest ratings and price target changes.

01/05/2019 Broker: Canaccord Genuity Old Rating: Sell New Rating: Sell Old Target: $11.0000 New Target: $9.0000 Maintain
01/05/2019 Broker: Piper Jaffray Old Rating: Underweight New Rating: Neutral Old Target: $15.0000 New Target: $11.0000 Upgrade
20/04/2019 Broker: BidaskScore Rating: Sell Downgrade
03/04/2019 Broker: Canaccord Genuity Old Rating: Hold New Rating: Sell Downgrade
30/03/2019 Broker: BidaskScore Rating: Hold Upgrade
19/02/2019 Broker: BidaskScore Rating: Hold Downgrade

The stock increased 1.32% or $0.15 during the last trading session, reaching $11.49. About 185,320 shares traded. Meridian Bioscience, Inc. (NASDAQ:VIVO) has risen 23.48% since May 8, 2018 and is uptrending. It has outperformed by 19.11% the S&P500.

Meridian Bioscience, Inc., a life science company, develops, makes, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide. The company has market cap of $488.20 million. The firm operates through Diagnostics and Life Science divisions. It has a 17.95 P/E ratio. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays that can be used in point-of-care settings under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the Premier brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand.

More notable recent Meridian Bioscience, Inc. (NASDAQ:VIVO) news were published by: Globenewswire.com which released: “Meridian Launches a New Inhibitor Tolerant qPCR Reagent to Significantly Simplify Molecular Diagnostic Workflows From Crude Samples – GlobeNewswire” on April 18, 2019, also Nasdaq.com with their article: “Intellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy – Nasdaq” published on April 29, 2019, Nasdaq.com published: “Motif Bio Signs Agreement with Lamellar Biomedical – Nasdaq” on May 01, 2019. More interesting news about Meridian Bioscience, Inc. (NASDAQ:VIVO) were released by: Nasdaq.com and their article: “HOOKIPA Appoints David R. Kaufman to its Board of Directors – Nasdaq” published on April 25, 2019 as well as Nasdaq.com‘s news article titled: “Better Buy: Editas Medicine vs. CRISPR Therapeutics – Nasdaq” with publication date: April 27, 2019.

Meridian Bioscience, Inc. (NASDAQ:VIVO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.